Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker said, days after a takeover bid from a private equity consortium collapsed.
"After careful reflection on both the process and the outcome of the recent takeover attempt, I have decided to step down to enable the board of Bavarian Nordic to focus on the company’s next phase of development," Mr. Debruyne said in a statement.
A takeover offer from a consortium including Nordic Capital and Permira was withdrawn in early November after it failed to secure the required 66 2/3% shareholder support, even though the board had recommended the deal.
The company announced that Vice Chair Anne Louise Eberhard has been appointed as the new Chair of the Board.
The leadership change comes as Bavarian Nordic reported a 32% increase in revenue for the first nine months of 2025 to 4.79 billion Danish Krone, driven by its travel health and public preparedness businesses.
Chief Executive Paul Chaplin said the company acknowledges "the decision by the shareholders to continue as an independent company in support of our existing strategy, which we remain fully committed to."
Bavarian Nordic said it expects total revenue of approximately 6 billion Danish Krone for the full year.
More from this issuer
Related coverage
Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker announced Thursday, days after a private equity takeover bid for the company collapsed.
A takeover offer for Danish vaccine maker Bavarian Nordic from a private equity consortium led by Nordic Capital and Permira has been withdrawn after failing to gain sufficient shareholder support.
A private equity consortium's takeover bid for Danish vaccine maker Bavarian Nordic is facing a crucial deadline, complicated by a major new European vaccine contract that could bolster the company's standalone value.
Bavarian Nordic has secured a new long-term contract to supply the European Union with up to 8 million doses of its smallpox and mpox vaccine over the next four years, the company said Friday.